## WST: West Pharmaceutical Services, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.0% below STRENGTH zone (4.0-10.0%); PEG 3.43 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($251.94)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Arrowstreet Capital Limited Partnership Has $28.23 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251207T083009 | Bullish | Relevance: 99%
- Arrowstreet Capital Limited Partnership significantly increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, now holding 129,030 shares valued at approximately $28.23 million. The medical instruments supplier recently reported strong Q2 earnings, exceeding analyst expectations with an EPS of $1.96 and revenue of $804.6 million, and has issued positive FY2025 guidance. Institutional investors own 93.90% of the stock, which currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $343.36.

**2. North Growth Management Ltd. Acquires 4,000 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251208T120842 | Bullish | Relevance: 98%
-  North Growth Management Ltd. increased its stake in West Pharmaceutical Services, Inc. by 16% in the second quarter, acquiring an additional 4,000 shares, bringing its total holdings to 29,000 shares valued at approximately $6.36 million. This move follows West Pharmaceutical Services' strong Q earnings report, beating analyst estimates for both EPS and revenue, and the company has issued positive FY2025 guidance. Several other institutional investors have also adjusted their positions in the medical instruments supplier, which currently holds a "Moderate Buy" consensus rating among analysts with an average price target of $343.36.

**3. West Pharmaceutical Services, Inc. $WST Stake Cut by Baird Financial Group Inc.**
- Source: MarketBeat | 20251206T085525 | Somewhat-Bullish | Relevance: 98%
-  Baird Financial Group Inc. reduced its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 7.2% during the second quarter, bringing their total ownership to 153,829 shares valued at $33.66 million. Despite this reduction, other institutional investors have acquired new positions or increased their stakes in the medical instruments supplier. Analysts maintain a "Moderate Buy" rating on WST, with an average price target of $343.36, and the company reported strong Q3 earnings, surpassing revenue and EPS estimates.

**4. XTX Topco Ltd Sells 8,822 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251206T125035 | Bullish | Relevance: 98%
-  XTX Topco Ltd significantly reduced its stake in West Pharmaceutical Services (NYSE:WST) by selling 8,822 shares, now holding 2,095 shares valued at $458,000. Despite this, institutional investors still own nearly 94% of the stock, with other funds increasing their positions. West Pharmaceutical Services recently surpassed quarterly earnings estimates and received a "Moderate Buy" consensus rating from analysts with an average target price of $343.36.

**5. Invesco Ltd. Boosts Stake in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251208T112026 | Somewhat-Bullish | Relevance: 97%
- Invesco Ltd. increased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 1.1% in the second quarter, bringing its total ownership to 959,525 shares valued at $209.94 million. Several other institutional investors also adjusted their stakes in the medical instruments supplier. The article highlights the company's financial performance, stock trading activity, and recent analyst ratings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.01M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.43 signals overvaluation risk, limited margin of safety. Forward P/E 34.6x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.4B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.43 |
| Forward P/E | 34.6 |
| Current P/E | 37.9 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -1.2% to -3.0% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.97% (CS: 32) | Weak |
| RSI_14 | 46.1 | Neutral |
| MACD Histogram | 0.46 | Bullish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 1.124x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $269.08
- **Stop Loss:** $251.94 (6.4% risk)
- **Target:** $286.22 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $7,803.32
- **Portfolio %:** 7.80%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*